Welcome to the e-CCO Library!

OP19: Gaps between ECCO quality standards of care and the real world: the E-QUALITY survey
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Fiorino, G.(1)*;
Created: Friday, 14 July 2023, 10:43 AM
OP19: Perinatal factors do not affect paediatric Inflammatory Bowel Disease risk: A Scottish nationwide cohort study using administrative health data 1981-2017
Year: 2020
Source: ECCO'20 Vienna
Authors: Christopher Burgess
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
OP20 The gut microbiota during biological therapy for inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Caenepeel1, S. Viera-Silva2, B. Verstockt3, K. Machiels3, N.A. Davani3, J. Sabino3,4, M. Ferrante3,4, J. Raes2, S. Vermeire3,4

Created: Thursday, 30 January 2020, 10:12 AM
OP20: Mucosal micoRNA profiles predict response to autologous stem-cell transplantation in Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Lewis*1, R. Jeffrey1, T. Kumagai1, C. J. Hawkey2, M. M. Clark2, M. Allez3, J. Satsangi4, G. Rogler5, A. Silver1, J. O. Lindsay6

Created: Friday, 22 February 2019, 9:41 AM
OP20: Mucosal microRNA profiles predict response to autologous stem-cell transplantation in Crohn’s Disease.
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Amy Lewis
Created: Tuesday, 28 May 2019, 3:32 PM
Files: 1
OP20: Perianal fistulas are characterised by expansion of interleukin-22 producing invariant natural killer T-cells and CD4+ T-cells which drive dysregulation of the extracellular matrix
Year: 2022
Source: ECCO'22
Authors: Constable, L.(1,2);Iqbal, N.(3,4);Cozzetto, D.(1);Hart , A.(3,4);Tozer, P.(3,4);Powell, N.(1);
Created: Friday, 11 February 2022, 3:52 PM
OP20: Risk and predictors of surgery in a newly diagnosed cohort of IBD patients in the biologic era: Results from the EpidemIBD study
Year: 2021
Source: ECCO'21 Virtual
Authors: Chaparro, M.(1);Garre, A.(1);Núñez Ortiz , A.(2);Diz-Lois Palomares, M.T.(3);Rodríguez, C.(4);Riestra, S.(5);Vela, M.(6); Benítez, J.M.(7);Fernández Salgado, E.(8);Sánchez Rodríguez, E.(9);Hernández, V.(10);Ferreiro-Iglesias, R.(11);Ponferrada Díaz, Á.(12);Barrio, J.(13); Huguet, J.M.(14);Arias, L.(15);Martín-Arranz, M.D.(16);Calvet, X.(17);Ginard, D.(18);Alonso-Abreu, I.(19);Fernández-Salazar, L.(20);Varela Trastoy, P.(21);Rivero, M.(22);Vera-Mendoza, I.(23);Vega, P.(24);Navarro, P.(25);Sierra, M.(26); Cabriada, J.L.(27);Aguas, M.(28);Vicente, R.(29);Navarro-Llavat, M.(30);Echarri, A.(31);Gomollón, F.(32);Guerra del Río, E.(33);Casanova, M.J.(1);Spicakova, K.(34);Ortiz de Zarate, J.(35);Alonso-Galán, H.(36);Barreiro-de Acosta, M.(11);Gisbert, J.P.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
OP20: The effects of upadacitinib on ulcerative colitis symptom resolution and fatigue normalization in patients with moderately to severely active ulcerative colitis: Phase 3 U-ACHIEVE and U-ACCOMPLISH results
Year: 2023
Source: ECCO’23 Copenhagen
Authors: D'Haens, G.(1)*;Tran, J.(2,3);Danese, S.(4);Rubin, D.T.(5);Aoyama, N.(6);Lügering, A.(7);Klaff, J.(3);Xuan, S.(3);Ilo, D.(3);Sanchez Gonzalez, Y.(3);Panes, J.(8);
Created: Friday, 14 July 2023, 10:43 AM
OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Nice1, N. Chanchlani2, H. Green2, C. Bewshea2, N. Kennedy2, T. Ahmad2, J. Goodhand2, T. McDonald1, M. Perry1

Created: Thursday, 30 January 2020, 10:12 AM
OP21: ABX464 is safe and efficacious in a proof of concept study in ulcerative colitis patients
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Jean-Marc Steens
Created: Tuesday, 28 May 2019, 3:32 PM
Files: 1
OP21: ABX464 is safe and efficacious in a proof-of-concept study in ulcerative colitis patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Vermeire1, X. Hébuterne2, P. Napora3, M. Wisniewska-Jarosinska4, G. Kiss5, A. Bourreille6, Z. Przemysław7, J. Nitcheu8, P. Gineste8, J-M. Steens*8, H. Ehrlich8

Created: Friday, 22 February 2019, 9:41 AM
OP21: COVID-19 morbidity/mortality and vaccination against SARS-CoV-2 in patients with Inflammatory Bowel Disease in Poland: Nationwide Data
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Piotr Kucha
Created: Friday, 14 July 2023, 2:22 PM
OP21: COVID-19 morbidity/mortality and vaccination against SARS-CoV-2 in patients with Inflammatory Bowel Disease in Poland: Nationwide Data
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kucha, P.(1,2)*;Walkiewicz, D.(3);Wieszczy, P.(2,4);Reguła, J.(1,2);Zagórowicz, E.(1,2);
Created: Friday, 14 July 2023, 10:43 AM
OP21: COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab
Year: 2022
Source: ECCO'22
Authors: Alexander, J.(1,2);Kennedy, N.(3,4);Ibraheim, H.(1,2);Anandabaskaran, S.(1,5);Saifuddin, A.(1,5);Castro Seoane, R.(1);Liu, Z.(1);Nice, R.(4,6);Bewshea, C.(4);D'Mello, A.(7);Constable, L.(1);Jones, G.R.(8,9);Balarajah, S.(1,2);Fiorentino, F.(10);Sebastian, S.(11,12);Irving, P.M.(13,14);Hicks, L.(1,2);Williams, H.(1,2);Kent, A.(15);Linger, R.(16);King, R.(16);Parkes, M.(16,17);Kok, K.(18);Patel, K.(19);Altmann, D.(20);Boyton, R.(21);Goodhand, J.(3,4);Hart, A.(5);Lees, C.(8,9);Ahmad, T.(3,4);Powell, N.(1,2);
Created: Friday, 11 February 2022, 3:52 PM
OP21: Predictive value of Milan Ultrasound Criteria in Ulcerative Colitis: A prospective observational cohort study
Year: 2021
Source: ECCO'21 Virtual
Authors: Allocca, M.(1);Dell’Avalle, C.(2);Furfaro, F.(2);Craviotto, V.(2);Zilli, A.(2);D'Amico, F.(2);Peyrin-Biroulet, L.(3);Fiorino, G.(1);Danese, S.(1)
Created: Wednesday, 2 June 2021, 4:12 PM